| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Trauma Centers | 21 | 2021 | 125 | 4.380 |
Why?
|
| Wounds and Injuries | 22 | 2021 | 191 | 4.080 |
Why?
|
| Traumatology | 11 | 2020 | 20 | 1.600 |
Why?
|
| Triage | 6 | 2019 | 34 | 1.510 |
Why?
|
| Multiple Organ Failure | 12 | 2009 | 31 | 1.460 |
Why?
|
| Injury Severity Score | 17 | 2021 | 131 | 1.400 |
Why?
|
| Critical Pathways | 5 | 2021 | 16 | 1.290 |
Why?
|
| Patient Transfer | 3 | 2019 | 43 | 1.270 |
Why?
|
| Neutrophils | 17 | 2005 | 183 | 1.090 |
Why?
|
| Florida | 12 | 2020 | 55 | 1.090 |
Why?
|
| Saline Solution, Hypertonic | 7 | 2003 | 13 | 0.920 |
Why?
|
| Transportation of Patients | 2 | 2017 | 29 | 0.910 |
Why?
|
| General Surgery | 4 | 2015 | 63 | 0.890 |
Why?
|
| Humans | 78 | 2022 | 28851 | 0.820 |
Why?
|
| Practice Guidelines as Topic | 7 | 2020 | 245 | 0.790 |
Why?
|
| Adult | 32 | 2021 | 8024 | 0.720 |
Why?
|
| Resuscitation | 7 | 2022 | 59 | 0.700 |
Why?
|
| Societies, Medical | 10 | 2021 | 93 | 0.670 |
Why?
|
| Trauma Severity Indices | 6 | 2016 | 37 | 0.670 |
Why?
|
| Appendectomy | 3 | 2017 | 14 | 0.660 |
Why?
|
| Appendicitis | 3 | 2017 | 14 | 0.660 |
Why?
|
| Academic Medical Centers | 3 | 2011 | 76 | 0.640 |
Why?
|
| Cervical Vertebrae | 2 | 2020 | 123 | 0.630 |
Why?
|
| Spinal Fractures | 2 | 2020 | 44 | 0.630 |
Why?
|
| Hypotension | 1 | 2019 | 20 | 0.620 |
Why?
|
| Physical Examination | 1 | 2020 | 53 | 0.610 |
Why?
|
| Algorithms | 8 | 2022 | 431 | 0.600 |
Why?
|
| Health Services Accessibility | 2 | 2012 | 120 | 0.580 |
Why?
|
| Wounds, Nonpenetrating | 7 | 2014 | 52 | 0.570 |
Why?
|
| Emergency Service, Hospital | 5 | 2021 | 122 | 0.570 |
Why?
|
| Cytotoxicity, Immunologic | 5 | 2002 | 30 | 0.560 |
Why?
|
| Clinical Decision-Making | 5 | 2021 | 63 | 0.540 |
Why?
|
| Retrospective Studies | 17 | 2022 | 2635 | 0.530 |
Why?
|
| Laparoscopy | 3 | 2015 | 156 | 0.530 |
Why?
|
| Male | 39 | 2022 | 13921 | 0.520 |
Why?
|
| Neurosurgery | 3 | 2019 | 76 | 0.520 |
Why?
|
| Delivery of Health Care | 2 | 2015 | 118 | 0.510 |
Why?
|
| Pediatrics | 1 | 2017 | 92 | 0.500 |
Why?
|
| Female | 34 | 2022 | 15624 | 0.500 |
Why?
|
| Hospitals, Pediatric | 3 | 2017 | 31 | 0.490 |
Why?
|
| Multiple Trauma | 6 | 2021 | 23 | 0.480 |
Why?
|
| Insurance Coverage | 1 | 2015 | 31 | 0.470 |
Why?
|
| Child | 13 | 2021 | 2287 | 0.460 |
Why?
|
| Mitogen-Activated Protein Kinases | 4 | 2003 | 88 | 0.430 |
Why?
|
| Middle Aged | 18 | 2021 | 7414 | 0.420 |
Why?
|
| Intensive Care Units | 2 | 2011 | 50 | 0.420 |
Why?
|
| Length of Stay | 4 | 2015 | 245 | 0.400 |
Why?
|
| Wounds, Penetrating | 2 | 2019 | 31 | 0.400 |
Why?
|
| United States | 14 | 2020 | 2222 | 0.390 |
Why?
|
| Emergency Medical Services | 4 | 2016 | 81 | 0.380 |
Why?
|
| Dental Clinics | 2 | 2011 | 2 | 0.370 |
Why?
|
| Dental Service, Hospital | 2 | 2011 | 2 | 0.370 |
Why?
|
| Surgery Department, Hospital | 1 | 2011 | 13 | 0.360 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2011 | 16 | 0.360 |
Why?
|
| Adolescent | 12 | 2021 | 3193 | 0.360 |
Why?
|
| Respiratory Burst | 5 | 2001 | 10 | 0.350 |
Why?
|
| Prospective Studies | 11 | 2021 | 1280 | 0.350 |
Why?
|
| Anticoagulants | 4 | 2021 | 297 | 0.350 |
Why?
|
| International Classification of Diseases | 2 | 2021 | 38 | 0.340 |
Why?
|
| Registries | 6 | 2019 | 396 | 0.340 |
Why?
|
| Patient Care Team | 2 | 2011 | 66 | 0.330 |
Why?
|
| Brain Injuries, Traumatic | 2 | 2021 | 46 | 0.320 |
Why?
|
| Critical Care | 5 | 2021 | 49 | 0.320 |
Why?
|
| Child, Preschool | 7 | 2021 | 1173 | 0.310 |
Why?
|
| Shock, Hemorrhagic | 7 | 2003 | 48 | 0.300 |
Why?
|
| Health Resources | 2 | 2011 | 19 | 0.300 |
Why?
|
| Infant, Newborn | 6 | 2021 | 916 | 0.290 |
Why?
|
| Craniocerebral Trauma | 2 | 2019 | 27 | 0.280 |
Why?
|
| Severity of Illness Index | 4 | 2020 | 465 | 0.280 |
Why?
|
| Health Care Rationing | 1 | 2008 | 5 | 0.280 |
Why?
|
| Aged | 9 | 2021 | 5598 | 0.280 |
Why?
|
| Postoperative Complications | 4 | 2022 | 634 | 0.280 |
Why?
|
| Physician's Role | 2 | 2006 | 29 | 0.280 |
Why?
|
| Infant | 5 | 2021 | 1025 | 0.270 |
Why?
|
| Child Abuse | 2 | 2021 | 92 | 0.270 |
Why?
|
| Needs Assessment | 3 | 2017 | 56 | 0.270 |
Why?
|
| Databases, Factual | 6 | 2020 | 268 | 0.260 |
Why?
|
| Colorado | 6 | 2006 | 51 | 0.260 |
Why?
|
| N-Formylmethionine Leucyl-Phenylalanine | 5 | 2001 | 10 | 0.250 |
Why?
|
| Blood Transfusion | 3 | 2021 | 77 | 0.250 |
Why?
|
| Orthopedics | 1 | 2006 | 20 | 0.250 |
Why?
|
| Neurilemmoma | 1 | 2006 | 13 | 0.250 |
Why?
|
| Retroperitoneal Neoplasms | 1 | 2006 | 9 | 0.250 |
Why?
|
| Vertebral Artery | 3 | 2021 | 16 | 0.240 |
Why?
|
| Risk Factors | 8 | 2020 | 2126 | 0.230 |
Why?
|
| Lung | 3 | 2005 | 382 | 0.230 |
Why?
|
| Abruptio Placentae | 1 | 2004 | 1 | 0.220 |
Why?
|
| Neutrophil Activation | 2 | 2001 | 6 | 0.220 |
Why?
|
| Blood Substitutes | 1 | 2004 | 9 | 0.220 |
Why?
|
| Intubation, Intratracheal | 1 | 2004 | 27 | 0.210 |
Why?
|
| Anemia | 1 | 2004 | 43 | 0.210 |
Why?
|
| Abdominal Injuries | 2 | 2019 | 35 | 0.210 |
Why?
|
| Hemoglobins | 1 | 2004 | 118 | 0.200 |
Why?
|
| Thymectomy | 1 | 2003 | 4 | 0.200 |
Why?
|
| Myasthenia Gravis | 1 | 2003 | 3 | 0.200 |
Why?
|
| Sternum | 1 | 2003 | 7 | 0.200 |
Why?
|
| Adrenal Insufficiency | 1 | 2002 | 4 | 0.200 |
Why?
|
| Hemorrhage | 2 | 2021 | 266 | 0.200 |
Why?
|
| Thymus Gland | 1 | 2003 | 54 | 0.190 |
Why?
|
| Patient Discharge | 3 | 2019 | 109 | 0.190 |
Why?
|
| Balloon Occlusion | 1 | 2022 | 4 | 0.190 |
Why?
|
| Hydrocortisone | 1 | 2002 | 89 | 0.190 |
Why?
|
| Cohort Studies | 4 | 2012 | 897 | 0.180 |
Why?
|
| Splenectomy | 1 | 2022 | 44 | 0.180 |
Why?
|
| Time Factors | 5 | 2013 | 1613 | 0.180 |
Why?
|
| Tomography, X-Ray Computed | 4 | 2021 | 481 | 0.180 |
Why?
|
| Physical Abuse | 1 | 2021 | 4 | 0.170 |
Why?
|
| Dental Care for Disabled | 2 | 2011 | 2 | 0.170 |
Why?
|
| Dental Care for Children | 2 | 2011 | 6 | 0.170 |
Why?
|
| Head Injuries, Penetrating | 1 | 2021 | 4 | 0.170 |
Why?
|
| Carotid Artery Injuries | 3 | 2005 | 12 | 0.170 |
Why?
|
| Emergency Treatment | 2 | 2014 | 26 | 0.170 |
Why?
|
| Cytoskeleton | 1 | 2001 | 45 | 0.170 |
Why?
|
| Clinical Protocols | 1 | 2021 | 46 | 0.170 |
Why?
|
| Emergencies | 2 | 2015 | 28 | 0.170 |
Why?
|
| Anesthesia | 1 | 2020 | 26 | 0.160 |
Why?
|
| Obesity | 1 | 2006 | 699 | 0.160 |
Why?
|
| Intracranial Hypertension | 1 | 2020 | 6 | 0.160 |
Why?
|
| Intracranial Pressure | 1 | 2020 | 12 | 0.160 |
Why?
|
| Surgical Procedures, Operative | 2 | 2014 | 49 | 0.160 |
Why?
|
| Abdominal Wound Closure Techniques | 1 | 2019 | 2 | 0.160 |
Why?
|
| First Aid | 1 | 2019 | 6 | 0.160 |
Why?
|
| Venous Thrombosis | 1 | 2020 | 98 | 0.160 |
Why?
|
| MAP Kinase Signaling System | 1 | 2000 | 95 | 0.160 |
Why?
|
| Quality Improvement | 1 | 2021 | 124 | 0.160 |
Why?
|
| Pulmonary Embolism | 1 | 2020 | 126 | 0.150 |
Why?
|
| Spinal Cord Injuries | 1 | 2020 | 69 | 0.150 |
Why?
|
| Battered Child Syndrome | 1 | 2019 | 1 | 0.150 |
Why?
|
| Young Adult | 5 | 2021 | 2833 | 0.150 |
Why?
|
| Practice Patterns, Physicians' | 2 | 2017 | 164 | 0.140 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 4 | 2003 | 45 | 0.140 |
Why?
|
| Superoxides | 7 | 2001 | 62 | 0.140 |
Why?
|
| Glasgow Coma Scale | 3 | 2021 | 22 | 0.130 |
Why?
|
| Oxygen | 3 | 2006 | 237 | 0.130 |
Why?
|
| Lymph | 3 | 2003 | 5 | 0.130 |
Why?
|
| Conservative Treatment | 1 | 2017 | 11 | 0.130 |
Why?
|
| Health Care Costs | 1 | 2017 | 50 | 0.130 |
Why?
|
| Guidelines as Topic | 2 | 2015 | 46 | 0.130 |
Why?
|
| Phospholipases A | 3 | 2001 | 6 | 0.130 |
Why?
|
| Accidents | 1 | 2016 | 5 | 0.130 |
Why?
|
| Fibrinolytic Agents | 2 | 2015 | 72 | 0.130 |
Why?
|
| Quality of Health Care | 1 | 2017 | 83 | 0.130 |
Why?
|
| CD18 Antigens | 3 | 2001 | 14 | 0.130 |
Why?
|
| Predictive Value of Tests | 3 | 2021 | 485 | 0.120 |
Why?
|
| Cells, Cultured | 5 | 2002 | 1022 | 0.120 |
Why?
|
| Unconsciousness | 1 | 2015 | 4 | 0.120 |
Why?
|
| Premedication | 1 | 2015 | 5 | 0.120 |
Why?
|
| Follow-Up Studies | 3 | 2007 | 1032 | 0.120 |
Why?
|
| Diagnostic Errors | 1 | 2015 | 32 | 0.120 |
Why?
|
| Hospital Costs | 1 | 2015 | 31 | 0.120 |
Why?
|
| Incidence | 3 | 2006 | 572 | 0.120 |
Why?
|
| Orthopedic Procedures | 1 | 2015 | 27 | 0.120 |
Why?
|
| Clinical Coding | 1 | 2015 | 7 | 0.120 |
Why?
|
| Thoracotomy | 2 | 2006 | 17 | 0.120 |
Why?
|
| Fractures, Bone | 1 | 2015 | 46 | 0.110 |
Why?
|
| Regression Analysis | 1 | 2015 | 211 | 0.110 |
Why?
|
| Social Class | 1 | 2015 | 81 | 0.110 |
Why?
|
| Caregivers | 1 | 2016 | 119 | 0.110 |
Why?
|
| Blood Preservation | 4 | 2003 | 9 | 0.110 |
Why?
|
| Aorta, Abdominal | 1 | 2014 | 15 | 0.110 |
Why?
|
| Comorbidity | 1 | 2015 | 261 | 0.110 |
Why?
|
| Comprehensive Dental Care | 2 | 2011 | 2 | 0.110 |
Why?
|
| General Practice, Dental | 2 | 2011 | 2 | 0.110 |
Why?
|
| Signal Transduction | 1 | 2001 | 1469 | 0.110 |
Why?
|
| Platelet Activating Factor | 3 | 2003 | 7 | 0.100 |
Why?
|
| Lymphatic System | 3 | 2002 | 11 | 0.100 |
Why?
|
| Venous Thromboembolism | 1 | 2015 | 136 | 0.100 |
Why?
|
| Logistic Models | 3 | 2020 | 410 | 0.100 |
Why?
|
| Macrophage-1 Antigen | 3 | 2001 | 9 | 0.100 |
Why?
|
| Systemic Inflammatory Response Syndrome | 2 | 2005 | 20 | 0.100 |
Why?
|
| Spleen | 2 | 2022 | 113 | 0.100 |
Why?
|
| Treatment Outcome | 4 | 2016 | 2426 | 0.100 |
Why?
|
| Regional Medical Programs | 1 | 2012 | 1 | 0.100 |
Why?
|
| Total Quality Management | 1 | 2012 | 11 | 0.100 |
Why?
|
| Organizational Innovation | 1 | 2012 | 20 | 0.100 |
Why?
|
| Geography | 1 | 2012 | 50 | 0.090 |
Why?
|
| Vulnerable Populations | 1 | 2013 | 48 | 0.090 |
Why?
|
| Program Development | 1 | 2012 | 87 | 0.090 |
Why?
|
| Efficiency, Organizational | 1 | 2011 | 13 | 0.090 |
Why?
|
| Program Evaluation | 1 | 2012 | 174 | 0.090 |
Why?
|
| Mesentery | 5 | 2002 | 9 | 0.090 |
Why?
|
| Hospital Administrators | 1 | 2011 | 1 | 0.090 |
Why?
|
| Specialties, Dental | 1 | 2011 | 1 | 0.090 |
Why?
|
| Interdepartmental Relations | 1 | 2011 | 1 | 0.090 |
Why?
|
| Dental Health Services | 1 | 2011 | 2 | 0.090 |
Why?
|
| Cerebral Angiography | 3 | 2005 | 38 | 0.090 |
Why?
|
| Facility Design and Construction | 1 | 2011 | 4 | 0.090 |
Why?
|
| Craniofacial Abnormalities | 1 | 2011 | 3 | 0.090 |
Why?
|
| Administrative Personnel | 1 | 2011 | 7 | 0.090 |
Why?
|
| Community-Institutional Relations | 1 | 2011 | 15 | 0.090 |
Why?
|
| Medical Staff, Hospital | 1 | 2011 | 22 | 0.090 |
Why?
|
| Medically Underserved Area | 1 | 2011 | 18 | 0.090 |
Why?
|
| Pancreatic Elastase | 2 | 2001 | 8 | 0.080 |
Why?
|
| Workload | 1 | 2011 | 43 | 0.080 |
Why?
|
| Referral and Consultation | 1 | 2011 | 98 | 0.080 |
Why?
|
| Apoptosis | 3 | 2003 | 780 | 0.080 |
Why?
|
| Specialties, Surgical | 2 | 2019 | 6 | 0.080 |
Why?
|
| Aged, 80 and over | 3 | 2021 | 2065 | 0.080 |
Why?
|
| Pregnancy | 2 | 2022 | 1254 | 0.070 |
Why?
|
| Enzyme Inhibitors | 4 | 2003 | 251 | 0.070 |
Why?
|
| Subacute Care | 1 | 2008 | 1 | 0.070 |
Why?
|
| District of Columbia | 1 | 2008 | 10 | 0.070 |
Why?
|
| Utilization Review | 1 | 2008 | 9 | 0.070 |
Why?
|
| Rats, Sprague-Dawley | 7 | 2003 | 554 | 0.070 |
Why?
|
| Aftercare | 1 | 2008 | 33 | 0.070 |
Why?
|
| Patient Selection | 2 | 2007 | 150 | 0.070 |
Why?
|
| Informed Consent | 1 | 2007 | 25 | 0.070 |
Why?
|
| In Vitro Techniques | 3 | 2003 | 242 | 0.060 |
Why?
|
| Hematocrit | 1 | 2006 | 26 | 0.060 |
Why?
|
| Lysophosphatidylcholines | 2 | 2003 | 4 | 0.060 |
Why?
|
| Hospital Charges | 1 | 2005 | 8 | 0.060 |
Why?
|
| Rats | 7 | 2003 | 1588 | 0.060 |
Why?
|
| Risk Assessment | 3 | 2021 | 631 | 0.060 |
Why?
|
| Urban Population | 1 | 2006 | 95 | 0.060 |
Why?
|
| Respiration Disorders | 1 | 2005 | 7 | 0.060 |
Why?
|
| Endothelium, Vascular | 3 | 2003 | 334 | 0.060 |
Why?
|
| Aneurysm, False | 1 | 2005 | 19 | 0.060 |
Why?
|
| Models, Organizational | 1 | 2005 | 18 | 0.060 |
Why?
|
| Kidney Diseases | 1 | 2005 | 61 | 0.060 |
Why?
|
| Heart Diseases | 1 | 2005 | 71 | 0.060 |
Why?
|
| Diagnosis, Differential | 1 | 2006 | 379 | 0.060 |
Why?
|
| Liver Diseases | 1 | 2005 | 52 | 0.060 |
Why?
|
| Ticlopidine | 1 | 2005 | 34 | 0.060 |
Why?
|
| Imidazoles | 2 | 2003 | 63 | 0.060 |
Why?
|
| Compartment Syndromes | 1 | 2004 | 7 | 0.060 |
Why?
|
| Forecasting | 1 | 2005 | 76 | 0.060 |
Why?
|
| Enteral Nutrition | 1 | 2004 | 23 | 0.060 |
Why?
|
| Enzyme Activation | 2 | 2003 | 267 | 0.060 |
Why?
|
| Disease Progression | 1 | 2006 | 477 | 0.050 |
Why?
|
| Body Mass Index | 1 | 2006 | 412 | 0.050 |
Why?
|
| Elective Surgical Procedures | 1 | 2005 | 74 | 0.050 |
Why?
|
| Erythropoietin | 1 | 2004 | 12 | 0.050 |
Why?
|
| Decision Making, Organizational | 1 | 2004 | 3 | 0.050 |
Why?
|
| Stents | 1 | 2005 | 121 | 0.050 |
Why?
|
| Organizational Policy | 1 | 2004 | 19 | 0.050 |
Why?
|
| Jehovah's Witnesses | 1 | 2004 | 5 | 0.050 |
Why?
|
| Pyridines | 2 | 2003 | 108 | 0.050 |
Why?
|
| Transfusion Reaction | 2 | 2001 | 10 | 0.050 |
Why?
|
| Lung Injury | 2 | 2001 | 32 | 0.050 |
Why?
|
| Cardiopulmonary Resuscitation | 1 | 2004 | 28 | 0.050 |
Why?
|
| Cross-Sectional Studies | 1 | 2008 | 995 | 0.050 |
Why?
|
| Abdomen | 2 | 2019 | 41 | 0.050 |
Why?
|
| Diaphragm | 1 | 2004 | 16 | 0.050 |
Why?
|
| Stroke | 2 | 2004 | 260 | 0.050 |
Why?
|
| Sepsis | 1 | 2004 | 86 | 0.050 |
Why?
|
| Caspases | 1 | 2003 | 43 | 0.050 |
Why?
|
| Hospital Mortality | 1 | 2004 | 159 | 0.050 |
Why?
|
| Immunity, Innate | 1 | 2005 | 231 | 0.050 |
Why?
|
| Intercellular Adhesion Molecule-1 | 1 | 2003 | 59 | 0.050 |
Why?
|
| Prognosis | 2 | 2021 | 811 | 0.050 |
Why?
|
| Electrocardiography | 1 | 2004 | 398 | 0.050 |
Why?
|
| Acute Disease | 2 | 2017 | 155 | 0.050 |
Why?
|
| Consensus | 1 | 2022 | 75 | 0.050 |
Why?
|
| Pancreatic Diseases | 1 | 2022 | 13 | 0.050 |
Why?
|
| Peroxidase | 1 | 2001 | 39 | 0.050 |
Why?
|
| Tetradecanoylphorbol Acetate | 1 | 2001 | 31 | 0.050 |
Why?
|
| Leukotriene B4 | 1 | 2001 | 2 | 0.040 |
Why?
|
| Pancreatectomy | 1 | 2022 | 58 | 0.040 |
Why?
|
| Isotonic Solutions | 1 | 2001 | 7 | 0.040 |
Why?
|
| Aorta | 1 | 2022 | 124 | 0.040 |
Why?
|
| Plasmapheresis | 1 | 2001 | 6 | 0.040 |
Why?
|
| Leukapheresis | 1 | 2001 | 3 | 0.040 |
Why?
|
| Early Medical Intervention | 1 | 2021 | 7 | 0.040 |
Why?
|
| Erythrocyte Transfusion | 1 | 2001 | 15 | 0.040 |
Why?
|
| Tyrosine | 1 | 2001 | 92 | 0.040 |
Why?
|
| Thromboembolism | 1 | 2021 | 57 | 0.040 |
Why?
|
| Tissue Extracts | 1 | 2000 | 7 | 0.040 |
Why?
|
| Decision Support Techniques | 1 | 2021 | 51 | 0.040 |
Why?
|
| Actins | 1 | 2001 | 99 | 0.040 |
Why?
|
| Benchmarking | 1 | 2020 | 33 | 0.040 |
Why?
|
| Probability | 1 | 2020 | 78 | 0.040 |
Why?
|
| Lymph Nodes | 1 | 2000 | 103 | 0.040 |
Why?
|
| Lipid Metabolism | 1 | 2001 | 150 | 0.040 |
Why?
|
| Interleukin-8 | 1 | 2000 | 45 | 0.040 |
Why?
|
| Radiography | 2 | 2014 | 203 | 0.040 |
Why?
|
| Standard of Care | 1 | 2019 | 12 | 0.040 |
Why?
|
| Phosphorylation | 1 | 2001 | 585 | 0.040 |
Why?
|
| Blood Coagulation | 1 | 2021 | 120 | 0.040 |
Why?
|
| Erythrocytes | 1 | 2000 | 89 | 0.040 |
Why?
|
| Pilot Projects | 1 | 2021 | 463 | 0.040 |
Why?
|
| Reactive Oxygen Species | 1 | 2001 | 292 | 0.040 |
Why?
|
| Skull Fractures | 1 | 2019 | 19 | 0.040 |
Why?
|
| Models, Biological | 1 | 2001 | 469 | 0.040 |
Why?
|
| Brain Concussion | 1 | 2019 | 53 | 0.040 |
Why?
|
| Cytokines | 1 | 2000 | 451 | 0.030 |
Why?
|
| Animals | 8 | 2005 | 10684 | 0.030 |
Why?
|
| California | 1 | 2017 | 70 | 0.030 |
Why?
|
| Atrial Fibrillation | 1 | 2021 | 404 | 0.030 |
Why?
|
| Health Care Surveys | 1 | 2015 | 67 | 0.030 |
Why?
|
| Cost-Benefit Analysis | 2 | 2005 | 115 | 0.030 |
Why?
|
| Heparin | 2 | 2005 | 111 | 0.030 |
Why?
|
| Age Factors | 1 | 2015 | 737 | 0.030 |
Why?
|
| Surveys and Questionnaires | 1 | 2017 | 997 | 0.020 |
Why?
|
| Quinacrine | 2 | 2001 | 2 | 0.020 |
Why?
|
| Cell Adhesion | 2 | 2002 | 139 | 0.020 |
Why?
|
| Education, Dental, Graduate | 1 | 2011 | 1 | 0.020 |
Why?
|
| Pediatric Dentistry | 1 | 2011 | 2 | 0.020 |
Why?
|
| Appointments and Schedules | 1 | 2011 | 8 | 0.020 |
Why?
|
| Schools, Dental | 1 | 2011 | 7 | 0.020 |
Why?
|
| Databases as Topic | 1 | 2011 | 22 | 0.020 |
Why?
|
| Phospholipases A2 | 2 | 2001 | 9 | 0.020 |
Why?
|
| Health Services Research | 1 | 2011 | 44 | 0.020 |
Why?
|
| Models, Theoretical | 1 | 2011 | 134 | 0.020 |
Why?
|
| Flow Cytometry | 2 | 2001 | 292 | 0.020 |
Why?
|
| Disease Models, Animal | 2 | 2005 | 1507 | 0.020 |
Why?
|
| Internship and Residency | 1 | 2011 | 250 | 0.020 |
Why?
|
| Presumed Consent | 1 | 2007 | 2 | 0.020 |
Why?
|
| Mental Competency | 1 | 2007 | 7 | 0.020 |
Why?
|
| Shock | 1 | 2007 | 18 | 0.020 |
Why?
|
| Neck Injuries | 1 | 2005 | 6 | 0.020 |
Why?
|
| Immunologic Factors | 1 | 2005 | 50 | 0.010 |
Why?
|
| Survival Analysis | 1 | 2006 | 288 | 0.010 |
Why?
|
| Edema | 1 | 2004 | 18 | 0.010 |
Why?
|
| Laparotomy | 1 | 2004 | 35 | 0.010 |
Why?
|
| Wounds, Stab | 1 | 2004 | 1 | 0.010 |
Why?
|
| Resuscitation Orders | 1 | 2004 | 9 | 0.010 |
Why?
|
| Transplantation, Autologous | 1 | 2004 | 42 | 0.010 |
Why?
|
| Wounds, Gunshot | 1 | 2004 | 18 | 0.010 |
Why?
|
| Pressure | 1 | 2004 | 90 | 0.010 |
Why?
|
| Heart Arrest | 1 | 2004 | 27 | 0.010 |
Why?
|
| Critical Illness | 1 | 2004 | 66 | 0.010 |
Why?
|
| Accidents, Traffic | 1 | 2004 | 28 | 0.010 |
Why?
|
| Rupture | 1 | 2004 | 12 | 0.010 |
Why?
|
| Combined Modality Therapy | 1 | 2004 | 303 | 0.010 |
Why?
|
| Carotid Arteries | 1 | 2004 | 54 | 0.010 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2005 | 191 | 0.010 |
Why?
|
| Survival Rate | 1 | 2004 | 432 | 0.010 |
Why?
|
| Caspase Inhibitors | 1 | 2003 | 8 | 0.010 |
Why?
|
| Caspase 3 | 1 | 2003 | 58 | 0.010 |
Why?
|
| Oligopeptides | 1 | 2003 | 97 | 0.010 |
Why?
|
| Osmolar Concentration | 1 | 2002 | 25 | 0.010 |
Why?
|
| Lung Diseases | 1 | 2003 | 43 | 0.010 |
Why?
|
| Bronchoalveolar Lavage Fluid | 1 | 2001 | 26 | 0.010 |
Why?
|
| Thoracic Duct | 1 | 2001 | 1 | 0.010 |
Why?
|
| Digestive System | 1 | 2001 | 16 | 0.010 |
Why?
|
| Blood Banks | 1 | 2001 | 2 | 0.010 |
Why?
|
| Tissue Preservation | 1 | 2001 | 3 | 0.010 |
Why?
|
| Chemotaxis, Leukocyte | 1 | 2001 | 15 | 0.010 |
Why?
|
| Drug Synergism | 1 | 2001 | 106 | 0.010 |
Why?
|
| Fibrinogen | 1 | 2001 | 50 | 0.010 |
Why?
|
| Specimen Handling | 1 | 2001 | 33 | 0.010 |
Why?
|
| Risk | 1 | 2001 | 138 | 0.010 |
Why?
|
| Polymyxin B | 1 | 2000 | 3 | 0.010 |
Why?
|
| NADPH Oxidases | 1 | 2000 | 69 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 2001 | 391 | 0.010 |
Why?
|
| Group II Phospholipases A2 | 1 | 2000 | 1 | 0.010 |
Why?
|
| Plasma | 1 | 2000 | 32 | 0.010 |
Why?
|
| Cell Communication | 1 | 2000 | 68 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 1999 | 302 | 0.010 |
Why?
|
| Lipids | 1 | 2000 | 218 | 0.010 |
Why?
|
| Antigens, CD | 1 | 1999 | 140 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 1999 | 739 | 0.010 |
Why?
|
| Oxidative Stress | 1 | 2001 | 677 | 0.010 |
Why?
|
| Inflammation | 1 | 2001 | 667 | 0.010 |
Why?
|
| Gene Expression Regulation | 1 | 1999 | 634 | 0.010 |
Why?
|